July 21, 2022 02:50 PM EDT

For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless

Zachary Brennan

Senior Editor

The battle over whether Biogen’s Alzheimer’s drug Aduhelm actually helps patients may never end, but in a recent SEC filing, Biogen, at least for accounting …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless

Zachary Brennan

Senior Editor

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?

For ac­count­ing pur­pos­es, Bio­gen says its $223M in­ven­to­ry of Aduhelm is ba­si­cal­ly worth­less

Zachary Brennan

Senior Editor

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?